Examining the unmet need in adults with severe asthma

Abstract

Asthma currently affects an estimated 300 million people worldwide and the number is expected to rise to 400 million by 2025. Asthma morbidity remains high and the economic burden is significant. Approximately 20% of patients have severe persistent asthma. As patients with severe asthma often have a variety of conditions that may coexist with or be mistaken for asthma, careful diagnosis and management are essential, and adhering to a protocol for investigations is helpful.For patients with severe persistent asthma, the Global Initiative for Asthma 2005 guidelines recommend the use of high-dose inhaled corticosteroids in combination with a long-acting b 2 -agonist, with one or more additional controller medications if required (step 4 therapy). However, recent studies have shown that asthma remains inadequately controlled in many patients with severe asthma, despite treatment in accordance with guidelines.Patients with severe asthma have the highest healthcare utilisation and mortality, and there is clearly an unmet need for the effective and safe treatment of patients with severe persistent allergic asthma who remain symptomatic despite optimised standard treatment. The latest guidelines suggest that omalizumab may address this unmet need.

Unmet Health Care Needs and Associated Factors among Patients with Hypertension and Those with Diabetes in Korea

“…즉, 소아 (Liberato et al, 2000), 아동집단 (Newacheck et al, 1998(Newacheck et al, , 2000Skinner et al, 2006), 청소년 (Liberats et al, 2000), 성인 (Shi & Stevens, 2005 ;Marina, 2009), 노인 (Philp et al, 1995 ;Alonso et al, 1997) 등 각 연령층을 대상으로 하거나, 천식 (Partridge, 2007), 뇌졸중 (op Reimer et al, 1999), 만성질환 (Sibley & Glazier, 2009), 급성질환과 만성질환 (Alam, 2007), 류마티스성 관절염 (Jacobi et al, 2004), 공황장애 (Crasker, 2005) (Kataoka et al, 2002), 에이즈치료서비스 (Bonuck, 2005 ;Adedigba et al, 2008), 장기요양서비스 (Lima & Allen, 2001), 일차의료서비스 (Zallman, et al, 2003 ;Diamant et al, 2004) …”

Anti-IgE: changing lives in clinical practice?

“…HAMELMANN [1] concludes that ''the antiinflammatory effects of omalizumab provide proof-of-concept of the key role played by IgE in allergic respiratory disease'' and that ''omalizumab represents a novel approach to the treatment of asthma, inhibiting the inflammatory cascade before it starts.'' PARTRIDGE [2] highlights the scale and impact of severe asthma and the need for careful diagnosis. The unmet needs in patients with severe asthma are illustrated by the findings of the Asthma Insights and Reality in Europe (AIRE) study [3], the Fighting for Breath survey [4], the International Asthma Patient Insight Research (INSPIRE) study [5] and the Gaining Optimal Asthma Control (GOAL) study [6].…”

“…The unmet needs in patients with severe asthma are illustrated by the findings of the Asthma Insights and Reality in Europe (AIRE) study [3], the Fighting for Breath survey [4], the International Asthma Patient Insight Research (INSPIRE) study [5] and the Gaining Optimal Asthma Control (GOAL) study [6]. PARTRIDGE [2] concludes that ''despite treatment with currently available therapy, there remains a patient group who have ongoing morbidity, require significant use of health services and are at risk of severe exacerbations'' and that ''omalizumab may help address the clear and unmet need for an effective and safe treatment of patients with severe persistent allergic asthma who remain symptomatic despite optimised standard treatment.'' BUHL [7] reviews the efficacy and safety of omalizumab in clinical trials.…”

“…BUHL [7] reviews the efficacy and safety of omalizumab in clinical trials. Particular focus is given to the Investigation of Omalizumab in Severe Asthma Treatment (INNOVATE) study [8], which enrolled patients with inadequately controlled severe persistent allergic asthma despite high-dose inhaled corticosteroids (ICS) in combination with a long-acting b 2 0.91; p50.042), severe exacerbation rates by 50% (0.24 versus 0.48; p50.002) and emergency visit rate by 44% (0.24 versus 0.43; p50.038) and significantly improved asthma-related quality of life (p,0.001), compared with placebo [8]. As patients enrolled in the INNOVATE study are the asthma patients with the greatest unmet need, these data are of great clinical importance and are highly encouraging.…”

Building the investment case for asthma R&D: the European Asthma Research and Innovation Partnership argument

“…Over 30 million people live with asthma in Europe [1] which is associated with considerable morbidity and an estimated annual cost of >€72.2 billion [2]. The global prevalence of asthma is expected to grow to over 400 million by 2025 [3]. Between now and 2020, if no major breakthroughs in research and the management of asthma are made, about 120 000 people in Europe will die as a result of asthma attacks, and 4 million will be hospitalized [2].…”